(Q34489699)

2 August 2017

title

Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease (English)

1 reference

2 August 2017

0 references

1 reference

M E Risner

1

1 reference

2 August 2017

A M Saunders

2

1 reference

2 August 2017

J F B Altman

3

1 reference

2 August 2017

G C Ormandy

4

1 reference

2 August 2017

S Craft

5

1 reference

2 August 2017

I M Foley

6

1 reference

2 August 2017

M E Zvartau-Hind

7

1 reference

2 August 2017

D A Hosford

8

1 reference

2 August 2017

A D Roses

9

1 reference

2 August 2017

Rosiglitazone in Alzheimer's Disease Study Group

10

1 reference

2 August 2017

publication date

31 January 2006

1 reference

2 August 2017

number of pages

9

1 reference

The Pharmacogenomics Journal

inferred from page(s)

published in

1 reference

2 August 2017

volume

6

1 reference

2 August 2017

issue

4

1 reference

2 August 2017

page(s)

246-254

1 reference

Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500369

7 January 2021

Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500369

7 January 2021

Apolipoprotein E alleles as risk factors in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500369

7 January 2021

Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500369

7 January 2021

Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500369

7 January 2021

Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500369

7 January 2021

Clinical and neuroimaging features of familial Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500369

7 January 2021

Mitochondrial abnormalities in Alzheimer brain: mechanistic implications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500369

7 January 2021

Transport of insulin across the blood-brain barrier: saturability at euglycemic doses of insulin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500369

7 January 2021

Hyperinsulinemia and risk of Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500369

7 January 2021

The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500369

7 January 2021

Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500369

7 January 2021

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500369

7 January 2021

Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500369

7 January 2021

Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500369

7 January 2021

Rivastigmine for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500369

7 January 2021

Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500369

7 January 2021

Donepezil therapy in clinical practice: a randomized crossover study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500369

7 January 2021

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500369

7 January 2021

Association of diabetes mellitus and dementia: the Rotterdam Study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500369

7 January 2021

Longitudinal association of vascular and Alzheimer's dementias, diabetes, and glucose tolerance.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500369

7 January 2021

Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500369

7 January 2021

Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500369

7 January 2021

Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500369

7 January 2021

Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500369

7 January 2021

Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500369

7 January 2021

Comparison of adipose tissue changes following administration of rosiglitazone in the dog and rat.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500369

7 January 2021

Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500369

7 January 2021

Thiazolidinedione activation of peroxisome proliferator-activated receptor gamma can enhance mitochondrial potential and promote cell survival.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500369

7 January 2021

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500369

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500369

1 reference

7 January 2021

Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500369

7 January 2021

A new rating scale for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500369

7 January 2021

Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500369

7 January 2021

Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500369

7 January 2021

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500369

7 January 2021

Lack of association between apolipoprotein E genoype and ischaemic stroke in a Scottish population.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500369

7 January 2021

Identifiers

DOI

10.1038/SJ.TPJ.6500369

1 reference

Dimensions Publication ID

2 August 2017

1037923527

0 references

1 reference